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Ca2-ATPase belongs to the family of P-type ATPases
and maintains low concentrations of intracellular Ca2.
Its reaction cycle consists of four main intermediates
that alternate ion binding in the transmembrane do-
main with phosphorylation of an aspartate residue in a
cytoplasmic domain. Previous work characterized an
ultrastable phosphoenzyme produced first by labeling
with fluorescein isothiocyanate, then by allowing this
labeled enzyme to establish a maximal Ca2 gradient,
and finally by removing Ca2 from the solution. This
phosphoenzyme is characterized by very low fluores-
cence and has specific enzymatic properties suggesting
the existence of a high energy phosphoryl bond. To
study the structural properties of this phosphoenzyme,
we used cryoelectron microscopy of two-dimensional
crystals formed in the presence of decavanadate and
determined the structure at 8-Å resolution. To our sur-
prise we found that at this resolution the low fluores-
cence phosphoenzyme had a structure similar to that of
the native enzyme crystallized under equivalent condi-
tions. We went on to use glutaraldehyde cross-linking
and proteolysis for independent structural assessment
and concluded that, like the unphosphorylated native
enzyme, Ca2 and vanadate exert a strong influence
over the global structure of this low fluorescence phos-
phoenzyme. Based on a structural model with fluores-
cein isothiocyanate bound at the ATP site, we suggest
that the stability as well as the low fluorescence of this
phosphoenzyme is due to a fluorescein-mediated cross-
link between two cytoplasmic domains that prevents
hydrolysis of the aspartyl phosphate. Finally, we con-
sider the alternative possibility that phosphate transfer
to fluorescein itself could explain the properties of this
low fluorescence species.
Intracellular Ca2 concentrations are maintained at low lev-
els by a group of ATP-dependent Ca2 pumps that belong to the
family of P-type ATPases (1, 2). These pumps maintain low
intracellular Ca2 concentrations as a baseline for signal trans-
duction pathways initiated by opening a variety of Ca2 chan-
nels. There are distinct groups of Ca2 pumps, or Ca2-ATP-
ases, in the plasma membrane and in membranes of the
sarcoplasmic/endoplasmic reticulum. The particular isoform
from sarcoplasmic reticulum (SR)1 of skeletal muscle is the
most extensively studied and represents an archetype for the
entire family. Biochemical studies have defined a series of
reaction intermediates that couple the energy of ATP hydroly-
sis within the cytoplasmic domain to alternations in the affin-
ity and accessibility of Ca2 binding sites within the membrane
domain (3). In the key step of the reaction cycle, this energy is
stored by the pump as an aspartyl phosphate and is used to
drive a global conformational change that simultaneously low-
ers the affinity of the Ca2 sites and exposes them to the
luminal side of the membrane, where the Ca2 ions are ex-
changed with protons. In fact, the reaction cycle appears to be
driven by a series of such conformational changes, which have
been deduced by biochemical and spectroscopic means and, in
some cases, directly visualized by electron microscopy (EM)
and x-ray crystallography (4, 5).
In its simplest form, this reaction cycle consists of four in-
termediates that alternate steps of ion binding/release with
those of phosphorylation/dephosphorylation of an aspartate
residue. This aspartate resides at the heart of the catalytic site,
and its phosphorylation by ATP is a critical step in transducing
chemical energy into conformational energy for Ca2 transport.
As outlined in Scheme 1, binding of cytoplasmic Ca2 is fol-
lowed by formation of a “high energy” phosphoenzyme, com-
monly denoted either EP[Ca2] or E1P[Ca2], in which two
Ca2 ions become “occluded” within the transmembrane do-
main, as denoted by brackets: [Ca2]. A global conformational
change to a low energy phosphoenzyme (E-P or E2-P) exposes
the Ca2 sites to the luminal side of the membrane and lowers
their affinity to the millimolar range; after Ca2 release and
proton binding, the phosphoenzyme is hydrolyzed to complete
the cycle. E1 and E2 are frequently used to distinguish two
hypothetical conformational states of the enzyme. E1 exists in
the first half of the cycle with high affinity Ca2 sites either
cytoplasmically oriented or occluded and the catalytic aspar-
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tate reactive toward nucleotides. E2 exists in the second half of
the cycle with the aspartate reactive toward inorganic phos-
phate and low affinity Ca2 sites either exposed to the lumen or
occluded with bound protons. Although the E1/E2 dichotomy
has been shown by Jencks and others to be an oversimplifica-
tion (6), it offers a framework for discussing the observed struc-
tural changes of the enzyme.
E1  2Cacyt3 E1(Ca2)  ATP3 E1P[Ca2] 
ADP3 E2-P(Ca2)3 E2-P  2Calum3 E2  Pi
SCHEME 1
In recent years, the structures of four main intermediates
have been defined by x-ray crystallography and electron mi-
croscopy (4, 5, 7). These structures have taught us a great deal
about the conformational changes that drive the reaction cycle
and about how binding of particular substrates dictates the
domain interactions responsible for these conformational
changes. Specifically, binding of Ca2 to transport sites induces
substantial changes to the backbone of several transmembrane
helices; these changes are relayed by M4 and M5 to the cyto-
plasmic domain containing the catalytic aspartate (P-domain),
causing its inclination and thus altering its association with
the other cytoplasmic domains (denoted N- and A-domains). As
a result, the aspartate is accessible to ATP bound in the N-
domain, and phosphate transfer produces a chemical bridge
between these two domains that indirectly induces Ca2 occlu-
sion. Loss of ADP disrupts this bridge and allows conserved
residues on the A-domain to interact with the covalently bound
phosphate group in the P-domain, thus indirectly disrupting
the Ca2 sites and opening the luminal gate for Ca2 release.
These same residues also orient a water molecule for hydrolysis
of the aspartyl phosphate, which loosens the interaction be-
tween cytoplasmic domains and leads to proton occlusion at the
transport site.
Despite these tremendous insights into the mechanisms of
energy coupling, questions remain about the transitions be-
tween these intermediates and about the precise physiological
context of each individual structure. In particular, the crystals
used for structure determination generally require surrogate
substrates to lock Ca2-ATPase into a defined conformation,
and crystal contacts have the potential to influence the juxta-
position of loosely bound domains. For instance, although crys-
tallization of the Ca2-bound state (E1(Ca2)) simply requires
high concentrations of Ca2 (8), the crystal contacts are likely
to be responsible in part for the wide spread between the
N-domain and the A-domain observed in the corresponding
structure. Also, the Ca2-free state (E2) was stabilized with
thapsigargin (TG) (9), which is documented to have significant
effects on binding of physiological ligands like ATP (10) and
phospholamban (11), and the high energy phosphoenzyme
(E1P) was trapped with the transition state analogue AlF4
 in
the presence of ADP (12), thus representing an analog of the
phosphoenzyme prior to nucleotide release (E1P[Ca2]ADP).
Finally, an analog of the low energy phosphoenzyme (E2P)
was crystallized with the MgF4
2 or the AlF4
 ligand bound to
the catalytic aspartate, again including TG (13, 14), which may
again be expected to exert a non-physiological influence over
the conformation. Similarly, lower resolution studies of the low
energy phosphoenzyme employed decavanadate as a crystalli-
zation agent, which bound at the interface of the three cyto-
plasmic domains (15).
An alternative procedure has been described for stabilizing a
phosphoenzyme derived from the high energy intermediate,
and structural characterization of this phosphoenzyme there-
fore holds the potential to shed light on the occlusion of calcium
and on other conformational changes of the phosphoenzyme
(16). Formation of this stabilized phosphoenzyme requires co-
valent labeling of Ca2-ATPase with fluorescein isothiocyanate
(FITC), which has long been known to be specific for Lys515
within the ATP binding site. Indeed, fluorescent changes of
FITC have often been used to monitor conformational changes
during the reaction cycle (17). Although FITC labeling prevents
phosphorylation by ATP, acetyl phosphate (AcP) can be used to
pump Ca2 and to produce high levels of the phosphoenzyme
once the membrane-bound enzyme becomes inhibited by high
luminal Ca2 concentration. Upon sudden chelation of Ca2
from the cytoplasmic side of the membrane, the FITC-labeled
Ca2-ATPase can then be markedly stabilized in a low fluores-
cence, phosphorylated form. Characterization of the resulting
species showed that, although it lacked bound Ca2 ions, it
could rapidly re-bind cytoplasmic Ca2 with high affinity and
transport this Ca2 directly across the membrane. This FITC-
labeled, low fluorescence species can thus be safely assumed to
derive from E1P[Ca2], or rather from the transient species
formed immediately prior to Ca2 occlusion (E1P(Ca2)). The
ability of decavanadate to produce two-dimensional crystals
within these vesicles (18) offers an opportunity to study the
structural properties of this phosphoenzyme and to relate it to
the other structures mentioned above.
For the current study, we optimized conditions for generat-
ing long, tubular crystals of the FITC-labeled, low fluorescence
phosphoenzyme, which included addition of TG and decavana-
date (19, 20), and solved its structure at 8-Å resolution by
cryoelectron microscopy and helical image analysis. Unexpect-
edly, the resulting structure appeared to be very similar at this
resolution to that previously determined for the unlabeled,
unphosphorylated enzyme under analogous conditions. We
then used proteolytic cleavage and glutaraldehyde cross-link-
ing to bring other approaches to bear on the structural analysis
and to study the influence of the crystallizing conditions
(namely decavanadate) on the conformation adopted by this
phosphoenzyme. In the absence of decavanadate, we obtained
conflicting results from proteolytic cleavage with trypsin and
proteinase K (PK), suggestive of a hybrid conformation,
whereas in the presence of decavanadate the results were con-
sistent with an E2-like conformation, as borne out by our cryo-
electron microscopic structure. We conclude that, like in the
unphosphorylated native enzyme, Ca2 and vanadate exert a
strong influence over the global structure of the low fluores-
cence phosphoenzyme. Also, although FITC is likely to mediate
a cross-link between N- and P-domains that serves to protect
the aspartyl phosphate, this cross-link is different than that
formed by ATP during phosphate transfer. Finally, we consider
the alternative possibility that FITC itself could have become
phosphorylated.
MATERIALS AND METHODS
SR was prepared from the white muscle of rabbit as described by
Inesi and Eletr (21) or by Champeil et al. (22). For most labeling
experiments, the preparation was diluted to 2 mg/ml protein in a buffer
containing 10 mM Tris-Tricine, pH 8, 0.3 M sucrose, 1 mM MgCl2, 10 M
CaCl2, and 16 M FITC, and incubated at 20 °C. The loss in ATPase
activity, measured using a coupled enzyme assay (23), was used to
follow the time course of labeling, which was generally complete after
15 min. The stabilized, high energy phosphoenzyme was generated as
previously described (18) in a buffer containing 0.1–0.5 mg/ml SR, 100
mM KCl, 5 mM MgCl2, and 50 mM MOPS at pH 7 and 20 °C. During this
process, FITC fluorescence was monitored with excitation and emission
wavelengths of 495 and 517 nm, respectively.
32P incorporation into Ca2-ATPase after reaction with [32P]-
acetylphosphate (synthesized according to Bodley et al. (24)) was deter-
mined by acid precipitation and filtration on Whatman filters followed
by washing with cold buffer and scintillation counting. Alternatively,
for monitoring the long term stability of this phosphoenzyme, samples
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were applied to a PD10 column pre-equilibrated with cold buffer to
remove excess of radioactivity; collected fractions were centrifuged at
70,000  g for 30 min in a Beckman rotor TLA 100.3, and the resultant
pellet was resuspended in crystallization buffer prior to incubation for
various periods and determination of the residual phosphorylation by
filtration and scintillation counting.
Tryptic cleavage was carried out at 0.75 or 2 mg/ml SR and at a
trypsin:SR weight ratio of 1:50 and was stopped by acid precipitation
using 4% perchloric acid. Samples were then loaded onto 12% Laemmli
gels for SDS-PAGE and stained with Coomassie Blue. Proteinase K
cleavage was carried out at 2 mg/ml SR and with a PK/SR weight ratio
of 1:67. SDS-PAGE after proteolysis arrest was performed as previously
described (25).
For the glutaraldehyde cross-linking experiments, SR vesicles (4
mg/ml) were labeled with FITC in 50 mM EPPS/tetramethylammonium
hydroxide, pH 8.0, 0.3 M sucrose, 0.1 mM CaCl2, 2 mM MgCl2, and 8
nmol/mg FITC for 20 min at room temperature. The suspension was
then adjusted to pH 7.5 with a small aliquot of concentrated maleic acid
and placed on ice. Formation of the low fluorescence species was per-
formed at room temperature in 50 mM MOPS/tetramethylammonium
hydroxide, pH 7.5, 0.3 M sucrose, 2 mM MgCl2, 0.1 mM CaCl2, 100 mM
NaCl, 2 mM AcP, and 0.4 mg/ml SR protein labeled with FITC; unla-
beled vesicles were also incubated as a control. Ca2 loading was
continued for 2 min, followed by addition of 5 mM EGTA to induce the
low fluorescence species. Cross-linking was performed with 1 mM glut-
araldehyde over 4 min in the same basic medium of 50 mM MOPS/
tetramethylammonium hydroxide, pH 7.5, 0.3 M sucrose, 2 mM MgCl2,
and 100 mM NaCl with various additions as indicated in the legend to
Fig. 4. The reaction was stopped by the addition of 1/10 dilution of 20%
SDS, 5.4 M 2-mercaptoethanol, and a trace of bromphenol blue. The
solubilized samples were subjected to SDS-PAGE with 7.5% acryla-
mide, and the proteins were stained with Coomassie Blue.
For preparing tubular crystals, FITC-labeled SR vesicles at 0.5
mg/ml protein were treated with 10 mM AcP, 5 mM MgCl2, and 0.1 mM
CaCl2 at room temperature, and the phosphoenzyme formed was then
stabilized by adding 5 mM EGTA followed by 10 M TG. The fluores-
cence signal from FITC was used to monitor the formation of the low
fluorescence species. Aliquots of 1 ml were then centrifuged at 70,000 
g for 30 min as above. After removing the supernatant, crystallization
buffer (typically 100 l) containing 20 mM imidazole, pH 7.2, 100 mM
KCl, 5 mM MgCl2, and 0.5 mM decavanadate was gently added to the
pellet without resuspension, followed by three cycles of freezing and
thawing to induce fusion of individual SR vesicles, thus producing
larger tubular crystals (20). Protein concentrations above 10 mg/ml
were required for significant fusion, with optimal results coming from
the much higher concentration within a gelatinous pellet. Also, sucrose
proved to be a strong inhibitor of fusion, and samples were therefore
washed thoroughly prior to crystallization. After freeze-thaw, the pellet
was resuspended at 1 mg/ml and incubated on ice overnight. For imag-
ing, 5 l of this sample was pipetted onto a perforated carbon film,
blotted with filter paper, and quick frozen with liquid ethane. Low dose
images were recorded at a magnification of 50,000 and defocus of
0.8–1.8 m with a CM200FEG electron microscope (FEI Corp., Eind-
hoven, Netherlands), screened by optical diffraction, and digitized at
14-m intervals with a SCAI densitometer (Intergraph Corp., Madison,
AL). After selecting well ordered tubes by optical diffraction, a group
with a common helical symmetry (characterized by Bessel orders of 23
and 7 for the 1,0 and 0,1 layer lines, respectively) was selected for
further processing. Defocus values were determined directly from the
images (26), and, after applying 2-fold symmetry averaging, an initial
three-dimensional structure was created using standard methods of
helical reconstruction. This structure was used as a reference for a suite
of programs designed to account for distortions along the tubes (27).
Thereafter, a new reference was generated and the distortions were
refined by a single iteration of these programs (15). Defocus values were
used to correct phases and to weight amplitudes along the layer lines.
These weighted data were then averaged and fully compensated for
defocus effects. The final data set was filtered, by removing data points
with phase deviations 65° from those expected for crystallographic
2-fold symmetry and was truncated at 7-Å resolution. This final struc-
ture was aligned with that of the unlabeled, unphosphorylated enzyme
by selecting a single molecule from the crystal lattice with a Gaussian
mask and then using the program suite Spider (28).
RESULTS
Formation and Characterization of the FITC-labeled, Low
Fluorescence Phosphoenzyme—Early work revealed the forma-
tion under specific conditions of a species of FITC-labeled Ca2-
ATPase with very low fluorescence (29), and, more recently,
this species was shown by kinetic analysis to derive from the
high energy phosphoenzyme after dissociation of the Ca2 ions
toward the cytosol (16). Fig. 1A shows a typical preparation in
which the fluorescence initially falls slowly as phosphoenzyme
is formed during active loading of SR vesicles with AcP. Upon
addition of EGTA, there is a further, precipitous reduction in
fluorescence by 60% to a state that is stabilized by TG. Fig.
1B shows that, if TG is added prior to EGTA, this low fluores-
cence species is not formed; similarly, collapse of the Ca2
gradient with Ca2 ionophore (A23187) reverses the initial
fluorescence decrease induced by AcP or prevents it from form-
ing if added prior to AcP (not shown). Fig. 1A also shows that
the low fluorescence state is maintained after subsequent ad-
dition of decavanadate (18). The fact that decavanadate actu-
ally binds to this species is documented by the slight decrease
in fluorescence caused by decavanadate addition. This decrease
is comparable, in relative terms, to that seen when decavana-
date is added to the high fluorescence species (not shown, but
see Ref. 30), and is not simply due to absorption of the excita-
tion wavelength by decavanadate.
We used [32P]AcP to quantify the amount of covalent phos-
phoenzyme formed under various conditions. During active
loading of SR vesicles with [32P]AcP, phosphoenzyme formation
was complete after 4 min, reaching a maximal value of 7 nmol
of phosphoenzyme/mg of protein (black circles, Fig. 1C). In the
presence of Ca2 ionophore A23187, the maximal level of phos-
phoenzyme was only 2 nmol/mg of protein (gray triangles), and
measurements in the absence of Ca2 (gray squares) demon-
strated the baseline for these measurements. Thus, the pres-
ence of a Ca2 gradient is a prerequisite for maximal phospho-
rylation of FITC-labeled ATPase by AcP. Furthermore, the
levels reached by active loading with AcP are close to stoichi-
ometric with the expected amount of FITC-labeled Ca2-
ATPase, and somewhat higher than those obtained with vesi-
cles preloaded with Ca2 and phosphorylated from [32P]Pi
(16, 18).
Fig. 1C also shows that when EGTA was followed by TG,
phosphoenzyme levels were completely stable over a 10-min
period (open circles), similar to previous results with Ca2-
preloaded vesicles phosphorylated from [32P]Pi (18). On the
other hand, when TG was added to the phosphoenzyme prior to
EGTA, thus preventing formation of the low fluorescence state
(Fig. 1B), the phosphoenzyme decayed with a half-life of 1–2
min (Fig. 1C, open triangles). A similar decay was observed
when Ca2 ionophore A23187 was added after phosphorylation
(Fig. 1C, open squares). A comparison of fluorescence levels
(Fig. 1, A and B) with phosphoenzyme levels (Fig. 1C) reveals
that the intermediate fluorescence species induced by AcP load-
ing, and the low fluorescence species induced by subsequent
addition of EGTA, both correspond to maximal levels of phos-
phoenzyme. Based on the fact that bound Ca2 could dissociate
from it, the intermediate fluorescence species has been hypoth-
esized to correspond to the normally transient enzymatic state
occurring immediately prior to occlusion of Ca2 (E1P(Ca2)),
perhaps in rapid equilibrium with the generally more stable
occluded state (E1P[Ca2]). The EGTA-induced decrease in
fluorescence reflects the removal of Ca2 from the former spe-
cies (16).
To test the stability of this phosphoenzyme under conditions
and time scales suitable for crystallization, we monitored 32P
retention by the FITC-labeled Ca2-ATPase upon incubation
for days at 0 °C in a crystallization buffer containing EGTA,
TG, and decavanadate. Fig. 1D shows that the level of phos-
phoenzyme, initially formed by active loading with AcP fol-
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lowed by 5 mM EGTA and 10 M TG, remained completely
stable over a week in the presence of decavanadate (solid
circles). The long term stability of this species, however, ap-
peared very sensitive to the residual concentration of free Ca2,
showing slightly lower stability at 0.5 and 1.0 mM EGTA (Fig.
1D, triangles and open circles, respectively) than at 5 mM
EGTA. This result is similar to the one previously found for
phosphoenzyme formed from Pi, which is also stable in the
presence of TG and decavanadate (18).
For optimal crystallization, we nevertheless observed that
the EGTA concentration had to be lowered from 5 mM (used for
producing the phosphoenzyme) to 0.5–1.0 mM. It is not clear
why an elevated EGTA concentration inhibited crystallization;
possibly, it was some direct effect of the polyanion on the
crystallization process. In any case, crystallization appeared to
be complete after overnight incubation on ice, at which time the
preparations were fast frozen for electron microscopy. As indi-
cated by our studies of phosphoenzyme stability under equiv-
alent conditions, virtually no hydrolysis occurred over this time
period (Fig. 1D), implying that essentially all ATPase mole-
cules remained phosphorylated under the conditions of
crystallization.
Structure of the FITC-labeled Phosphoenzyme—Images of
thirteen tubular crystals were selected for image processing
and three-dimensional reconstruction using methods of helical
image analysis (27). These images consistently showed optical
diffraction to at least 15-Å resolution. Unlike earlier work, only
crystals conforming to a single helical symmetry were used for
Fourier-Bessel reconstruction, allowing us to average data
from all the tubes in Fourier space. Based on the 2-fold sym-
metry phase residual, we judged the resolution of our data to
extend to 7-Å resolution (Table I).
This reconstruction revealed that the overall shape of the
FITC-labeled, phosphorylated Ca2-ATPase (Fig. 2A) is sur-
prisingly similar to that previously seen for the E2VO4 confor-
mation of unlabeled, unphosphorylated Ca2-ATPase crystal-
lized under similar conditions either in the presence of TG (Fig.
2B) or in its absence (31–33). Also shown in Fig. 2C is a
structure for FITC-labeled Ca2-ATPase that was not phospho-
rylated prior to crystallization (15). A noticeable hole is visible
FIG. 1. Formation of a low fluorescence phosphoenzyme from FITC-ATPase using AcP. For the fluorescence studies (A and B),
FITC-labeled SR vesicles were suspended at 0.1 mg/ml in 2 ml of buffer consisting of 50 mM MOPS-KOH at pH 7.0, 100 mM KCl, and 5 mM MgCl2.
For each trace, 90 M EGTA was first added, followed by 100 M Ca2 (open arrowheads), thus producing the small, but well known
Ca2-dependent FITC fluorescence changes as a calibration. Thereafter, phosphorylation was initiated by adding 10 mM AcP. A, after allowing the
system to reach AcP-dependent steady-state fluorescence, the low fluorescence species (to be studied by electron microscopy) was generated by
adding 2 mM EGTA, followed by 10 M TG. Subsequent addition of decavanadate did not affect the stability of the low fluorescence form, although
it further reduced its fluorescence slightly. B, the low fluorescence species is not formed if 10 M TG is added prior to 2 mM EGTA. [32P]AcP was
then used to document the formation and stability of the low fluorescence phosphoenzyme. C, FITC-labeled SR vesicles (1 mg/ml) were incubated
either in the presence (black circles) or in the absence (gray squares) of Ca2, or in the presence of Ca2 together with the Ca2 ionophore A23187
(gray triangles), prior to the addition of 10 mM of [32P]AcP at time zero. After 5 min, samples in the presence of Ca2 were subjected to sequential
additions of 5 mM EGTA followed by 10 M TG (open circles), of TG followed by EGTA (open squares), or of 5% (w/w) A23197 (open triangles). D,
long term stability of the phosphoenzyme formed as shown in A and C and incubated in crystallization buffer was measured in 5 mM (solid circles),
1 mM (open circles), or 0.5 mM (inverted triangles) EGTA. Unreacted [32P]AcP was eliminated using a PD10 column pre-equilibrated in AcP-free
phosphorylation buffer. The collected fractions were centrifuged (40,000 rpm in a TLA 100.3 rotor for 30 min), and the pellet was resuspended at
a protein concentration of 30 mg/ml in 50 mM MOPS-KOH, pH 7.0, 5 mM MgCl2 and the stated concentrations of EGTA. After several cycles of
freeze-thaw, the protein was diluted to 3 mg/ml in crystallization buffer, including TG and decavanadate, and stability of the covalent
phosphoenzyme was determined at various times by filtration on Whatman filters as described under “Materials and Methods.”
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in the cytoplasmic domain of the latter structure, which reflects
the absence of decavanadate binding to this molecule (15), as
will be further discussed below. TG was used for all the struc-
tures shown in Fig. 2, because it increases the abundance of
tubular crystals present in the preparation; nevertheless, these
crystals form in the absence of TG and we have previously
shown that TG has no apparent effect on the disposition of the
cytoplasmic domains (33).
We adopted two methods for comparing the FITC-labeled,
phosphorylated Ca2-ATPase to the non-labeled, E2VO4TG
form. First, we examined the detailed fit of an atomic model for
Ca2-ATPase that was originally built for the E2VO4TG con-
formation (Fig. 3, pdb code 1KJU from Ref. 15). Using the
program SITUS (34) to calculate a correlation coefficient for the
fit, we found that this model fitted E2VO4TG and the present
structure equally well (0.643 versus 0.649), thus precluding any
significant domain displacements or significant reorganization
of transmembrane helices. To look for more subtle differences
between the two structures, we aligned the corresponding den-
sity maps in real space and calculated a difference map. All of
the difference densities were found at the edges of the molec-
ular envelope and probably reflect slight inaccuracies in align-
ment and differences in resolution between the two maps (Fig.
3A). Although some of these differences may indicate small
structural changes, e.g. a small cavity within the phosphoryl-
ation domain of the FITC-labeled phosphoenzyme that was not
observed in E2VO4TG, all of these are very much smaller than
the obvious movements of cytoplasmic domains and transmem-
brane helices that characterize comparisons of E2VO4TG,
E1(Ca2), and E2TG (4). In comparison, a large, obvious nega-
tive difference density is visible in the control difference map
between FITC-E2VO4TG and E2VO4TG (red contours in Fig.
3B), which results from the absence of decavanadate in the
former structure (15). A similar set of difference densities was
observed in comparing FITC-E2VO4TG with FITC-EPVO4TG
(data not shown). Thus, although FITC displaces decavanadate
from its intramolecular binding site on unphosphorylated
Ca2-ATPase, formation of the low fluorescence phosphoen-
zyme appears to reverse this effect. This difference in deca-
vanadate binding to the phosphorylated and non-phosphory-
lated crystallized FITC-labeled ATPase must indicate a change
in domain surfaces in this region of the molecule (see below).
Structural Insights from Glutaraldehyde Cross-linking and
Proteolytic Digestion—Cross-linking the N- and P-domains of
Ca2-ATPase by glutaraldehyde has been shown to be espe-
cially sensitive to the conformation of Ca2-ATPase. In partic-
ular, cross-linking of Lys492 in the N-domain to Arg678 in the
P-domain is most efficient in the E1P conformation and occurs
with lower efficiency in E1(Ca2) and E2, whereas addition of
either ATP or decavanadate to E2, or formation of E2-P,
strongly inhibits cross-linking (35–37). In addition to showing
these effects on control, unlabeled Ca2-ATPase samples, Fig.
4 shows results of glutaraldehyde cross-linking of FITC-labeled
Ca2-ATPase, as detected by the appearance of a band migrat-
TABLE I
Statistics of helical reconstructions
FITC-EPVO4TG E2VO4TG FITC-E2VO4TG
No. tubes 13 58 12
No. repeats 22 95 22
Resolution
Å
Residuala
(degrees)
Data includedb
%
Residual
(degrees)
Data included
%
Residual
(degrees)
Data included
%
40 2.36 100 1.14 96 1.39 99
30 3.94 100 1.71 96 2.60 97
20 9.80 96 4.32 91 9.45 94
14 21.59 89 14.52 89 21.26 87
10 29.63 82 23.85 85 30.00 83
9 31.34 83 34.60 78
8 32.50 77 34.00 80 35.68 77
7 33.40 76
6 36.33 77
a Phase residual of final data set compared to ideal 2-fold symmetry (i.e., 0 or 180°).
b Percentage of data remaining after removing data with phase error with respect to 2-fold symmetry 65°.
FIG. 2. Three-dimensional reconstructions of the Ca2-ATPase in three different states. The structure of the low fluorescence
phosphoenzyme determined in the present work (A, F-EPVO4TG) is shown together with structures of the native enzyme (B, E2VO4TG) and of
the FITC-labeled, unphosphorylated enzyme (C, F-E2VO4TG), previously presented by Xu et al. (15). Crystallization conditions are the same in
all three cases and include decavanadate and TG. Although at somewhat different resolutions (see Table I), all three structures have the same
shape, suggesting that the domains have not significantly moved as a result of FITC labeling or phosphorylation. The only obvious difference is
the hole in the middle of the cytoplasmic domain in F-E2VO4TG, which results from the exclusion of decavanadate from this site in this state.
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ing at 125 kDa. In general, cross-linking is less efficient after
labeling with FITC, but some general conclusions can still be
drawn. Cross-linking occurs with lower efficiency for E1(Ca2)
(lanes 2 and 8) and E2 (lanes 3 and 9). Although ATP strongly
inhibits cross-linking of unlabeled Ca2-ATPase (lane 4), ATP
cannot bind to FITC-labeled Ca2-ATPase and therefore has no
effect on cross-linking (lane 10). In contrast, cross-linking of the
E1P species formed at steady-state levels by AcP was almost
equally efficient with labeled and unlabeled Ca2-ATPase
(lanes 6 and 12, respectively); for FITC-labeled Ca2-ATPase,
this steady-state species corresponds to the intermediate levels
of fluorescence shown in Fig. 1A. However, formation of the low
fluorescent phosphoenzyme from this steady-state E1P spe-
cies produced very low cross-linking levels (lane 13), suggesting
that the low fluorescence species no longer resembles E1P,
from the point of view of glutaraldehyde cross-linking.
Proteolytic cleavage is another classic method for distin-
guishing conformations of Ca2-ATPase. We first considered
digestion with proteinase K, which has a pair of diagnostic
cleavage sites on the segments connecting M2 and M3 to the A
domain (38). The latter site (Thr242-E2
43) represents the dom-
inant cleavage site in the E1(Ca2) conformation, thus producing
the p83C fragment, whereas the former site (Leu119-Lys120) is
specifically cleaved in E2 and produces the p95C fragment in
addition to the p83C fragment, particularly after binding of TG
(Fig. 1 and Supplemental Material from Ref. 39). PK cleavage
is dramatically reduced upon addition of nucleotide in the
presence of Ca2 (E1(Ca2)ATP), upon formation of E1P-like
conformations, E2-P, or E2-P-like species formed with or-
thovanadate or decavanadate in the absence of Ca2 (E2decaV)
(40, 41). Here, we treated FITC-labeled Ca2-ATPase with PK
after either inducing the low fluorescence phosphoenzyme (Fig.
5A, lanes 5–8), or stabilizing the E2 conformation (Fig. 5A,
lanes 1–4). AcP, EGTA, and TG were added in both cases,
although EGTA was added after AcP to generate the phos-
phoenzyme but before AcP to simply stabilize an E2 species.
The resulting proteolytic patterns were indistinguishable, with
both species creating a large amount of the p95C fragment, as
is characteristic of E2TG. We therefore conclude that even
though the low fluorescence phosphoenzyme is derived from
the high energy phosphoenzyme, it resembles neither a normal
E1P conformation nor an E1 conformation, from the point of
view of susceptibility to PK.
We finally turned to digestion with trypsin. Trypsin initially
cleaves Ca2-ATPase at Arg505 to produce A and B fragments,
which are not separated in our gel system, and fragment A is
then cleaved at the T2 site to produce A1 and A2 subfragments.
For native Ca2-ATPase, the susceptibility of the T2 site,
which is at Arg198 on a loop not far from the conserved
181TGES184 motif, is most sensitive to conformation (40–42).
E1(Ca2) is most susceptible to cleavage at T2, whereas forma-
tion of an E2vanadate complex in the absence of Ca
2 (using
either orthovanadate or decavanadate, and presumably resem-
bling E2-P) completely blocks cleavage (40). Nucleotide binding
to E1(Ca2) or formation of the E1(Ca2)AlF4
 complex (presum-
ably resembling E1P[Ca2]) also protects the T2 site, but to a
much lesser degree (41). Thus states analogous to E2-P are
distinguished by their resistance to cleavage at T2 with the
remaining states showing relatively subtle differences. Fig. 5B
shows that the tryptic digestion patterns of FITC-labeled Ca2-
ATPase was also sensitive to the ligands present. Lanes 1–6
show that the susceptibility of the T2 site after FITC labeling
was similar to that of the native enzyme, i.e. most susceptible
in the E1(Ca2) (lane 2) and completely blocked in the presence
of TG and either decavanadate or orthovanadate (lanes 5 and 6;
it is however unclear whether decavanadate per se was respon-
sible for this, or whether contaminating orthovanadate in the
decavanadate solution was the active species). In the phospho-
rylated, low fluorescence species (lane 7), the T2 site remained
highly susceptible to cleavage. However, in the presence of
decavanadate (lane 8), the T2 site was blocked completely,
almost as efficiently as in the non-phosphorylated E2-type de-
cavanadate complex. This suggests that the low fluorescence
FIG. 4. Cross-linking with glutaraldehyde. SR vesicles were pre-
pared in the native unlabeled state, labeled with FITC, or as the low
fluorescence phosphoenzyme, as indicated. These vesicles were sus-
pended at 0.4 mg/ml in a medium defined under “Materials and Meth-
ods,” were reacted with glutaraldehyde (1 mM) for 4 min and then were
subjected to SDS-PAGE followed by Coomassie Blue staining. Addi-
tional reagents added during the reaction are indicated at the top of
each lane with concentrations as follows: 0.1 mM CaCl2, 5 mM EGTA,
0.02 mM ATP, 0.04 mM decavanadate. The formation of a cross-link
between Lys492 in N-domain and Arg678 in P-domain results in the
formation of a species with an apparent molecular mass of 125 kDa as
marked to the left of the gel.
FIG. 3. EM densities fitted with atomic coordinates and EM
difference maps. The ribbon diagram in both panels represents the
pdb coordinates 1KJU that were previously fitted to the structure of
E2VO4TG (15). Here, it is shown to fit equally well the density found
for the unphosphorylated native E2VO4TG (B, yellow envelope) and the
density found for the low fluorescence FITC-labeled phosphoenzyme
F-EPVO4TG (A, green envelope). Superposed with these densities, dif-
ference maps are also shown, as indicated: (F-EPVO4TG  E2VO4TG)
in panel A, for FITC-labeled phosphoenzyme relative to unphosphoryl-
ated unlabeled Ca2-ATPase, and (F-E2VO4TG  E2VO4TG) in panel
B, for unphosphorylated FITC-labeled Ca2-ATPase relative to unphos-
phorylated unlabeled Ca2-ATPase. In both panels, the blue and red
surfaces correspond to positive and negative difference densities, re-
spectively, at a level of 5. A difference map between FITC-labeled
phosphoenzyme and FITC-labeled unphosphorylated enzyme (F-
E2VO4TG  F-EPVO4TG) looks essentially the same as panel B (not
shown): the only significant difference occurs at the intramolecular
decavanadate site.
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species is not a rigidly defined conformation but is still influ-
enced by the binding of certain ligands and especially by deca-
vanadate under the conditions used for crystallization.
DISCUSSION
Previous work reported conditions for forming a stable, phos-
phorylated form of Ca2-ATPase: after labeling with FITC, the
enzyme is allowed to generate a steady-state Ca2 gradient by
cycling with AcP and is then treated with EGTA and TG to
form an ultrastable, low fluorescence phosphoenzyme (Fig. 1).
This low fluorescence phosphoenzyme is characterized by a
high energy phosphoryl group in the sense that the protein is
poised to transport Ca2 as soon as Ca2 binds to the cytoplas-
mically oriented, high affinity transport sites (16). Further-
more, this species is distinct from E2-P, which either binds
luminal Ca2 with low affinity or, in the absence of luminal
Ca2, is readily hydrolyzed into the unphosphorylated E2 spe-
cies. Thus, we had reasonable expectation that the FITC-la-
beled, low fluorescence phosphoenzyme would represent a good
analogue for the E1P conformation. In the current work, we
used [32P] to document the stability of this phosphoenzyme
under conditions of two-dimensional crystallization (Fig. 1) and
reconstructed the three-dimensional structure at 8-Å resolu-
tion by cryoelectron microscopy (Fig. 2). Although this resolu-
tion is not sufficient to reveal atomic details, it does document
the juxtaposition of cytoplasmic domains and the organization
of transmembrane helices. Unexpectedly, we found that the
conformation of the crystallized low fluorescence phosphoen-
zyme was in fact indistinguishable, at this resolution, from that
of the native enzyme crystallized under equivalent conditions
(Fig. 3). We then also used glutaraldehyde cross-linking and
proteolysis as independent means of assessing the conforma-
tion of the low fluorescence species, and of potentially shedding
light on the effect of decavanadate on its structure (Figs. 4 and
5). These studies suggested that the low fluorescence species
was a hybrid, retaining characteristics of both Ca2-bound and
Ca2-free species, and that its conformation was sensitive to
the binding of decavanadate to the cytoplasmic domains.
Conformational Effects of FITC—The very low fluorescence
of the species used for crystallization has previously been at-
tributed either to an increase in pKa of the phenolic 3-OH of
fluorescein through hydrophobic/negatively charged interac-
tions or to a salt link with basic residues surrounding the ATP
pocket. Such interactions lead to a drastically stabilized aspar-
tyl phosphate, presumably due to enhanced association of N-
and P-domains (16). In particular, intimate communication
between N- and P-domains would explain the interdependence
of phosphoenzyme stability (in the P-domain) and fluorescein
fluorescence (in the N-domain). The ATP binding pocket from
the x-ray structure of E1ADPAlF4
 is shown in Fig. 6A with
fluorescein substituted for ADP. Arg489, Lys492, Arg560, and
Arg678 are all nearby and represent potential ligands to clamp
the phenolic residues at the ends of the xanthenolone ring of
fluorescein (43), and stacking against the nearby Phe487 repre-
sents another potential stabilizing element (44). Specific inter-
action with these charged and/or aromatic side chains may
account for fluorescent quenching after formation of E1P.
Arg678 is normally cross-linked to Lys492 by glutaraldehyde,
especially in E1P-like structures, and these residues are very
close indeed in the E1ADPAlF4
 structure (Fig. 6A). In the
E2VO4TG structure (Fig. 6B), the -carbons for these residues
have moved 13 Å further apart, which is consistent with the
poor efficiency of cross-linking in E2P-like reaction intermedi-
ates (35–37). According to our model, Arg678 is within range to
interact with fluorescein in both conformations, which is a
likely explanation for the inhibition of glutaraldehyde cross-
linking after FITC labeling and after formation of the low
fluorescence phosphoenzyme (Fig. 4). If so, FITC would be
serving as a physical link between N- and P-domains, which
may account for the extreme stability of the aspartyl phosphate
in the low fluorescence state by perhaps altering the arrange-
ment of catalytic residues in the phosphorylated P-domain, as
well as restricting access of the A-domain to the catalytic site.
Normally, phosphorylation induces a characteristic conforma-
tional change in the P-domain that allows its key residues to be
gathered at the catalytic site. Additionally, the conserved
181TGES184 sequence in the A-domain is able to approach the
catalytic site in E2-P and has been shown to have a critical role
in orienting water for hydrolysis of the phosphoenzyme follow-
ing Ca2 release to the lumen (13, 39, 45). More generally,
structural comparison of several Ca2-ATPase conformations
indicates that the A-domain is highly mobile and undergoes
FIG. 5. Digestion of FITC-labeled Ca2-ATPase with proteinase
K (A) or trypsin (B). A, for PK digestion, 2 mg/ml FITC-SR protein
was suspended in 100 mM MOPS-NaOH, 5 mM Mg2, and 0.1 mM Ca2,
at pH 6.5 and 20 °C. For lanes 1–4, 10 mM EGTA, 0.02 mg/ml TG, and
10 mM AcP were added sequentially, resulting in a control, high fluo-
rescence, E2-like state. For lanes 5–9, 10 mM AcP was added, followed
first by 10 mM EGTA after 2 min, and then by 0.02 mg/ml TG, to form
the stable low fluorescence phosphorylated species. Then, samples were
digested with 0.03 mg/ml PK for the time intervals indicated at the top
of each lane (minutes). The low fluorescence state was stable for at least
20 min after protease addition. B, for trypsin digestion, 0.75 mg/ml
FITC-SR was suspended in 50 mM MOPS-NaOH, 0.1 mM Ca2, 5 mM
Mg2, and 20% glycerol at pH 6.6 and 20 °C. For lanes 3–6, 5 mM EGTA
was added; 10 M TG (lane 3), 10 mM Pi (lane 4), 10 M TG and 0.01 mM
orthovanadate (lane 5), or 10 M TG and 1 mM decavanadate (lane 6)
were also added to produce the indicated intermediates. The low fluo-
rescence phosphoenzyme (FITC-EP, lanes 7–8) was generated by add-
ing 10 mM AcP followed after 2 min by 5 mM EGTA, and after another
30 s by 10 M TG (lane 7) or 10 M TG and 1 mM decavanadate (lane 8).
For all samples, digestion was carried out with 0.015 mg/ml trypsin
(ratio of 1/50 w/w) for 1 min. Lane 9 shows molecular mass standards.
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large rotations during the binding of Ca2 to transport sites or
during formation of the phosphoenzyme, thus allowing the
181TGES184 loop to move from a solvent-exposed position in E1
conformations to a buried position within the catalytic pocket
in E2-P (4, 13). Similarly, there is evidence that the N-domain
is mobile in the E1(Ca2) state (46) but becomes tethered to the
P-domain during phosphate transfer from ATP, which elicits
Ca2 occlusion (12, 47). Although the FITC-labeled Ca2-
ATPase is apparently still able to undergo all these steps and
transport Ca2, the kinetics of Ca2 occlusion appear to be
altered, presumably due to the formation of a long-lived reac-
tion intermediate immediately preceding closure of the cyto-
plasmic gates, which could be attributed to the persistence of
the N/P-domain interface at the point in the cycle when ADP
would normally be released (16).
Conformational Effects of Decavanadate—Decavanadate is
required for two-dimensional crystallization of all three forms
of Ca2-ATPase shown in Fig. 2: native Ca2-ATPase, FITC-
labeled unphosphorylated Ca2-ATPase, and the low fluores-
cence phosphorylated species first studied here. Decavanadate
has been shown to bind at two sites in the two-dimensional
crystals of native Ca2-ATPase: one site mediating intermolec-
ular contacts at a 2-fold symmetry axis and a second intramo-
lecular site at the interface between N-, P-, and A-domains (48).
Normally, FITC labeling completely displaces decavanadate
from the intramolecular site (Fig. 2C) (15), a result consistent
with a lowered binding stoichiometry for decavanadate meas-
ured under analogous conditions (49). Nevertheless, in the
structure of the low fluorescence phosphoenzyme (FITC-
EPVO4, Fig. 2A), density for decavanadate was clearly ob-
served. This result must reflect some subtle alteration in the
N-, P-, and A-domain interfaces upon formation of the low
fluorescence state. Although the basis for binding the nega-
tively charged decavanadate molecule (V10O29
6) is uncertain,
an atomic model for the unlabeled enzyme crystallized with
decavanadate (pdb code 1KJU) shows positively charged resi-
dues from all three cytoplasmic domains surrounding the bind-
ing pocket, namely Arg489, Lys492, and Arg560 from the N-
domain, Arg678 from the P-domain and Arg174 from the
A-domain. Lys515 and Lys205 are also in the vicinity and could
provide additional ligands depending on the orientation of their
side chains. As previously mentioned, several of these residues
may also interact with FITC; Arg489, Lys492, and Arg678 have
also been specifically implicated in ATP ligation (37, 50) and
Arg489 and Arg678 interact with AMPPCP and ADP in the
relevant structures (12, 47). Thus, competition for these li-
gands could explain the competitive binding of decavanadate,
ATP, and FITC to the unphosphorylated Ca2-ATPase as
shown, for example, by the displacement of TNP-AMP by de-
cavanadate (51).
Upon phosphorylation and formation of the low fluorescence
species, these ligands and their corresponding domains appear
to accommodate the binding of decavanadate, producing small
but distinct fluorescence changes (Fig. 1), reducing the acces-
sibility of the T2 proteolytic site (Fig. 5), and inducing crystal-
lization. In fact, decavanadate probably further stabilizes the
N-/P-domain interface. It is conceivable that in the low fluores-
cence phosphoenzyme, FITC no longer prevents decavanadate
from binding at the intramolecular site, because specific inter-
action of FITC with one of the residues at this domain interface
holds FITC in a favorable position. Protection of the T2 site of
FITC-EP by decavanadate is consistent with rotation of the
A-domain to the position seen in our new structure, which is
indistinguishable from the position adopted by the unlabeled
enzyme or by FITC-labeled, unphosphorylated enzyme (Figs. 2
and 3). Yet, the fact that the cytoplasmic domains adopt the
same configuration in FITC-labeled unphosphorylated enzyme
(F-E2VO4TG in Fig. 2), despite the lack of decavanadate bind-
ing, indicates that decavanadate is not stabilizing an artificial
structure. In this respect, it is also notable that the 1KJU
structure, which was fitted into the EM density derived from
two-dimensional crystals of E2VO4TG, does not show any sig-
nificant reorganization of cytosolic domains, compared with the
structure of a decavanadate-free E2P-like species recently de-
rived from three-dimensional crystals of E2MgF4TG (47). Fur-
thermore, although decavanadate does cause a small decrease
FIG. 6. Model for the fluorescein binding site. A, FITC (in or-
ange) was placed into the ADP binding site of the x-ray structure for
E1ADPAlF4
 (pdb code 1T5T) such that one 3-O phenolic oxygen su-
perimposed with the -phosphate of ADP and the isothiocyanate group
on the benzoate ring was within binding range of Lys515. This specula-
tive model for the E1FITCAlF4
 species shows positively charged resi-
dues surrounding the xanthenolone ring of FITC, and the in-line dis-
position of its phenolic oxygen with AlF4 (red); the position of one of the
Mg2 ions is also shown (yellow). Arg678 is in close proximity to Lys492,
which is consistent with the high efficiency of glutaraldehyde cross-
linking observed for the E1P intermediate. B, an equivalent view of
the E2FITCVO4TG structure modeled from the cryoelectron micros-
copy (pdb code 1KJU), in which FITC occupies the same position within
the N-domain. In the 1KJU structure, the P-domain (magenta) is pulled
away from the N-domain (green) producing a large distance between
FITC and Asp351. Also, the -carbon for Arg678 is 13 Å further away
from Lys492, accounting for the low efficiency of glutaraldehyde cross-
linking in E2P-like species. Nevertheless, the 3-O phenolic group of
FITC is still within range for interaction with Arg678. All views repre-
sent a 17-Å-thick slab at the interface of the N- and P-domains. Insets
provide an overview of the entire molecule with the N-, P-, and A-do-
mains shown in green, magenta, and yellow, respectively; M4 and M5
are colored blue, and other transmembrane helices are white. The figure
was prepared with Swiss PDB Viewer and PovRay.
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in fluorescence, probably due to Förster transfer, it does not
fundamentally disrupt the low fluorescence state or the chem-
ical stability of the aspartyl phosphate (18).
What Does Proteolysis Tell Us About the Structure?—Our
tryptic digestion experiments suggest that, prior to the addi-
tion of decavanadate, the low fluorescence species has a rela-
tively exposed T2 cleavage site, perhaps similar to E1. How-
ever, the pattern of PK digestion most closely resembles that of
E2. The T2 site (Arg
198) is on a loop in the mobile A-domain,
which is held firmly against the P-domain in E2VO4 or is
rotated by 90° in E1(Ca2) and thus exposed to solvent. Simi-
larly, the PK site (Leu-Lys120) is on the link between the
A-domain and transmembrane helix M2, and its susceptibil-
ity is influenced by interaction of the M2 and M3 links with
the P-domain (39). The hybrid behavior of the low fluores-
cence species might reflect structural flexibility arising 1)
from the lack of Ca2 at the transport sites and 2) from the
inability to form a true E2-P structure at the catalytic site.
Such flexibility was previously invoked to explain the fact that
E1(Ca2)AMPPCP is considerably more susceptible to PK than
E1(Ca2)ADPAlF4
, despite having virtually identical atomic
structures; in this case, the susceptibility to PK also correlated
with inability to occlude Ca2 (12). In the case of our low
fluorescence species, flexibility of its A-domain is consistent
with the effectiveness of either orthovanadate or decavanadate
in inhibiting tryptic cleavage at the T2 site and in stabilizing
the A-domain in the position seen in our structure. PK proteo-
lytic patterns for the low fluorescence phosphoenzyme are in-
distinguishable from those for the unphosphorylated enzyme in
the absence of Ca2 and in the presence of TG (with or without
FITC), which is consistent with the ability of vanadate to
induce similar structures for all three forms (Fig. 2). We con-
clude that the conformation of the low fluorescence phosphoen-
zyme is significantly influenced by the various ligands studied,
i.e. orthovanadate or decavanadate, and of course Ca2, as it
binds to transport sites and induces the enzyme to reenter the
catalytic cycle.
Ca2 Is a Dominant Determinant of Ca2-ATPase Conforma-
tion—X-ray structures show that Ca2 has a profound effect on
the transmembrane helices, causing curving of the central M5
helix and large displacements of M1, M2, M3, M4, and M6.
These changes are presumably initiated by recruitment of li-
gands to bind the pair of Ca2 ions and relaxation of these same
ligands into a significantly different configuration in the ab-
sence of Ca2. In contrast, these structures show that the
presence of ligands at the catalytic site have relatively minor
effects on the structure of the membrane helices (e.g. compare
E2TG and E2MgF4TG in Ref. 13, and compare E1(Ca2) and
E1AMPPCP in Ref. 47). These observations are in line with the
fact that TG binds only to Ca2-free, E2-like species of Ca
2-
ATPase (52, 53), and the ability of TG to stabilize the FITC-
labeled, low fluorescence species suggests that in this species
the transmembrane helices adopt an E2-like configuration,
which is likely to be a direct result of Ca2 dissociation from the
FITC-labeled E1P species present at steady state. Indeed, the
membrane domain in our current structure of the low fluores-
cence phosphoenzyme is identical to that of E2VO4, at least at
6- to 7-Å resolution, and certainly distinct from the structure
expected for an E1 conformation. The lesson would seem to be
that Ca2 is the primary determinant of the global conforma-
tion of Ca2-ATPase, given its definitive influence over the
entire transmembrane domain and its ability to control cyto-
plasmic domain associations and thus ligand binding. Obvi-
ously, the cytoplasmic domains are also able to exert some
influence over the membrane domain, but this appears to be
confined to relatively minor structural changes that open and
close gates that control access of Ca2 to the binding sites, as
well as to some as yet undefined mechanism of altering Ca2
affinity during the E1P[Ca2] to E2-P[Ca] transition.
An Alternative Hypothesis: Phosphotransfer to Fluorescein—
A completely different explanation for the stability of the phos-
phoenzyme could be that Ca2 removal from the FITC-labeled
species formed from AcP at steady state (with intermediate
fluorescence) elicits unexpected phosphate transfer from
Asp351 to a phenolic oxygen of the covalently attached fluores-
cein. Because the pH sensitivity of the spectral properties of
fluorescein is due to protonation or deprotonation of one of the
phenolic oxygens, covalent attachment of phosphate at the
same site on fluorescein would no doubt also alter its spectral
properties: phosphorylation of fluorescein is already known to
result in low fluorescence (54), and 3-methylfluorescein mono-
phosphate is a commonly used non-fluorescent but fluorogenic
substrate for phosphatases as well as for Ca2-ATPase (55).
Furthermore, phosphate transfer from Asp351 to FITC would
provide an elegant explanation for our findings that high fluo-
rescence and low fluorescence forms of FITC-ATPase have sim-
ilar proteolytic patterns and cross-linking properties. Indeed,
the model of fluorescein docked in the structure of
E1ADPAlF4
 (Fig. 6A) shows that the 3-O of the xanthenolone
ring can be superimposed with the terminal oxygen of the
-phosphate, which is in line with the -phosphate analog
AlF4
. Upon removal of Ca2, Arg678 might thus provide an
alternative interaction for the covalently attached fluorescein
monophosphate. After re-addition of Ca2, the attached fluo-
rescein monophosphate could act as a substrate for re-phospho-
rylation of Asp351, thus allowing Ca2-ATPase to re-enter the
catalytic cycle. There is a precedent for such a mechanism:
TNP-ATP covalently attached to Lys492 through a light-de-
pendent azido reaction is capable of serving as a substrate upon
the addition of Ca2 (56). We investigated this possibility by
analyzing tryptic digests of FITC-labeled Ca2-ATPase pre-
pared from control and low fluorescent phosphoenzyme prepa-
rations. The two main fluorescein-peptides were found to have
indistinguishable retention times on C18 reverse-phase high
performance liquid chromatography and virtually identical ab-
sorption spectra, as characterized by the optical density ratio at
210 and 495 nm (data not shown). Furthermore, the pH de-
pendence of absorbance in 8 M urea of the covalently attached
fluorescein was similar whether it was derived from control or
from the low fluorescence species, which in turn was like that
of FITC itself: pKa values were close to 7, and were quite
different from the pKa of 4.9 for fluorescein monophosphate in
solution (54) (data not shown). Based on these results, phos-
phate transfer from Asp351 to the fluorescein ring does not
appear to be the most likely explanation for the appearance of
our low fluorescence species; rather, we attribute the low fluo-
rescence to a unique interaction between N- and P-domains
that serves to protect the aspartyl phosphate bond. However,
covalent binding to Ca2-ATPase of the putative fluorescein
monophosphate could well modify its properties in unexpected
ways, and the alternative hypothesis should perhaps be kept
in mind.
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